Collegium Pharmaceutical Inc

Insider sale of 20 Collegium shares is routine; the company’s strong CNS pipeline, solid valuation, and large holdings keep it attractive for mid‑cap biotech investors.

BOHLIN GAREN G’s latest insider buy at Collegium Pharmaceutical signals confidence after the company’s annual meeting, suggesting potential upside from new strategic moves.

Collegium Pharmaceutical’s insider buys and sales, plus its new AZSTARYS stimulant launch, reveal a strategy to boost revenue, cut costs and win payer value‑based contracts—watch how this may lift stock value in 2026.

Collegium’s modest insider sell‑off coincides with a $650 M acquisition of AZSTARYS—an opportunity for milestone cash flows, cross‑selling synergies, and future revenue growth.

Collegium insider sale shows a measured risk‑management move while its CNS & respiratory pipeline gains FDA fast‑track status, signaling potential upside once milestones hit.